
Johnson & Johnson (JNJ:NYSE) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI’s, and Recent Trends
Description
Report Summary
Johnson & Johnson (JNJ:NYSE) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI’s, and Recent Trends Report is a comprehensive and easily accessible overview of Johnson & Johnson's business operations. It provides a detailed analysis of the company's financial and strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.
The report begins with in-depth information about Johnson & Johnson, including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.
Next, the report assesses Johnson & Johnson's strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. The PESTLE analysis evaluates the external factors impacting the company's operations and market environment. Additionally, By integrating these strategic analyses, the report offers a comprehensive understanding of Johnson & Johnson's overall strategic standing and supports informed decision-making and strategic planning.
The report also covers Johnson & Johnson's financial analysis basis of latest income statement, balance sheet, and cash flow statement. Key financial ratios related to profitability, asset turnover, credit, market, and long-term solvency are outlined, providing guidance for investment decisions. Furthermore, the report compares Johnson & Johnson's financial parameters with those of its competitors, offering a unique analysis of the competitive landscape. This information helps manage the business environment and improve sales activities by gaining insight into competitors' operations.
Finally, the report includes recent news and deal activities undertaken by Johnson & Johnson, enhancing awareness of the company's business trends, growth perspectives, and more.
Key Highlights
Johnson and Johnson operates as a healthcare focused company that researches, develops, manufactures, and sells various products in the healthcare field worldwide. Johnson and Johnson operates in three main business segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers over-the-counter medicines and personal care products. The Pharmaceutical segment provides prescription drugs. The Medical Devices segment offers surgical equipment, orthopedic products, cardiovascular devices, and vision care products. Johnson and Johnson offers a broad range of health care products across three business segments: Consumer Health, Pharmaceutical, and Medical Devices. Some of the key products and services include over-the-counter medicines like Tylenol, Band-Aid, Benadryl, and Zyrtec; prescription drugs for immunology, infectious diseases, neuroscience, oncology, and cardiovascular diseases; medical devices for orthopedics, surgery, cardiovascular disease, and vision care including joint replacements, surgical tools and equipment, contact lenses, and laser refractive surgical technologies. Founded in 1887, the company is headquartered in New Brunswick, New Jersey, United States.
Johnson and Johnson in the News:-
Johnson & Johnson (JNJ:NYSE) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI’s, and Recent Trends Report is a comprehensive and easily accessible overview of Johnson & Johnson's business operations. It provides a detailed analysis of the company's financial and strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.
The report begins with in-depth information about Johnson & Johnson, including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.
Next, the report assesses Johnson & Johnson's strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. The PESTLE analysis evaluates the external factors impacting the company's operations and market environment. Additionally, By integrating these strategic analyses, the report offers a comprehensive understanding of Johnson & Johnson's overall strategic standing and supports informed decision-making and strategic planning.
The report also covers Johnson & Johnson's financial analysis basis of latest income statement, balance sheet, and cash flow statement. Key financial ratios related to profitability, asset turnover, credit, market, and long-term solvency are outlined, providing guidance for investment decisions. Furthermore, the report compares Johnson & Johnson's financial parameters with those of its competitors, offering a unique analysis of the competitive landscape. This information helps manage the business environment and improve sales activities by gaining insight into competitors' operations.
Finally, the report includes recent news and deal activities undertaken by Johnson & Johnson, enhancing awareness of the company's business trends, growth perspectives, and more.
Key Highlights
Johnson and Johnson operates as a healthcare focused company that researches, develops, manufactures, and sells various products in the healthcare field worldwide. Johnson and Johnson operates in three main business segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers over-the-counter medicines and personal care products. The Pharmaceutical segment provides prescription drugs. The Medical Devices segment offers surgical equipment, orthopedic products, cardiovascular devices, and vision care products. Johnson and Johnson offers a broad range of health care products across three business segments: Consumer Health, Pharmaceutical, and Medical Devices. Some of the key products and services include over-the-counter medicines like Tylenol, Band-Aid, Benadryl, and Zyrtec; prescription drugs for immunology, infectious diseases, neuroscience, oncology, and cardiovascular diseases; medical devices for orthopedics, surgery, cardiovascular disease, and vision care including joint replacements, surgical tools and equipment, contact lenses, and laser refractive surgical technologies. Founded in 1887, the company is headquartered in New Brunswick, New Jersey, United States.
Johnson and Johnson in the News:-
- 14-Feb-2025 - Johnson and Johnson to Resume U.S. VARIPULSE Cases
- 13-Feb-2025 - New nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody diseases
- 13-Feb-2025 - Johnson and Johnson Statement on Phase 3 E.mbrace Study
- 03-Feb-2025 - CHMP recommends subcutaneous RYBREVANT (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer
- 21-Jan-2025 - SPRAVATO (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression
- Tactical Analysis:- Various strategic frameworks to gain insights into a company's competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
- Business Strategy:- Contributes to shaping the company's overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
- Financial Position:- Provide valuable information on the financial performance and investor sentiment surrounding the company. Indicating the level of confidence and expectations in the company's future prospects. These components collectively contribute to understanding the financial health and market perception of the company.
- Company Fundamentals:- These fundamentals offer valuable insights into the company's history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
- Competitive Landscape:- An identification of the company's main competitors, providing insights into the competitive landscape it operates in.
- Comprehensive Understanding of the Johnson & Johnson's internal and external factors through SWOT analysis, PESTLE analysis, Financial Analysis, and Competitors Benchmarking.
- Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
- Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
- Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
- Financial Performance Evaluation provides crucial insights into key financial ratios and trends, supporting better financial decision-making and resource allocation.
- Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.
- Johnson & Johnson Porter's Five Forces Analysis
- Johnson & Johnson VRIO Analysis
- Johnson & Johnson BCG Analysis
- Johnson & Johnson Segmentation, Targeting and Positioning (STP) Analysis
- Johnson & Johnson Ansoff Matrix Analysis
Table of Contents
111 Pages
- COMPANY EXECUTIVE SUMMARY
- Table of Contents
- Tables
- Charts
- Johnson & Johnson - Key Company Facts
- Johnson & Johnson -
- Company Description
- Johnson & Johnson - Top Executives
- Johnson & Johnson- Top Executives Biographies
- Johnson & Johnson- Head Office & Locations
- Head Office - Country
- Key Subsidiaries
- Key Joint Ventures
- Johnson & Johnson - Products and Services
- Products
- Johnson & Johnson - Historic Events
- Johnson & Johnson - Company's Mission and Vision
- Mission
- Vision
- Johnson & Johnson - Corporate Strategy
- Johnson & Johnson - Business Description
- Innovative Medicine
- MedTech
- Johnson & Johnson - ESG Spotlight
- Environment
- Social
- Corporate Governance
- Johnson & Johnson - SWOT Analysis
- Overview
- Strengths
- Weaknesses
- Opportunities
- Threats
- Johnson & Johnson - PESTLE Analysis
- Overview
- Political Factors
- Economic Factors
- Social Factors
- Technological Factors
- Legal Factors
- Environmental Factors
- Johnson & Johnson - Financial Deep Dive
- Share Price Trend - Feb-2024 to Feb-2025 (Average Share Closing Price)
- Profit and Loss Statement
- Summary of Profit and Loss Statement
- Balance Sheet
- Summary of Balance Sheet
- Cash Flow Statement
- Summary of Cash Flow Statement
- Key Financial Ratio Analysis
- Johnson & Johnson - Ratio Charts
- Activity Ratio Charts
- Growth Ratios Charts
- Leverage Ratio Charts
- Liquidity Ratio Charts
- Profitability Ratio Charts
- Competing Players
- Snapshot of Competing Players
- GE HealthCare Technologies, Inc.
- Key Company Facts
- Company Description
- Pfizer Inc.
- Key Company Facts
- Company Description
- Sanofi S.A.
- Key Company Facts
- Company Description
- The Procter & Gamble Company
- Key Company Facts
- Company Description
- Merck & Co., Inc.
- Key Company Facts
- Company Description
- Johnson & Johnson - In the News
- 14-Feb-2025 - Johnson & Johnson to Resume U.S. VARIPULSE Cases
- 13-Feb-2025 - New nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody diseases
- 13-Feb-2025 - Johnson & Johnson Statement on Phase 3 E.mbrace Study
- 03-Feb-2025 - CHMP recommends subcutaneous RYBREVANT (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer
- 21-Jan-2025 - SPRAVATO (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression
- 18-Dec-2024 - Johnson & Johnson submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA (ibrutinib) in adult patients with previously untreated mantle cell lymphoma (MCL) who are eligible for autologous stem cell transplant
- 17-Dec-2024 - Johnson & Johnson Participates in the Inauguration of World Health Organization (WHO) Academy to Improve Training and Education of Health Workers Globally
- 16-Dec-2024 - Johnson & Johnson submits application seeking U.S. FDA approval of SIMPONI (golimumab) for the treatment of pediatric ulcerative colitis
- 12-Dec-2024 - U.S. FDA Expands Indication for Impella Heart Pumps to Treat Pediatric Patients
- 09-Dec-2024 - CARVYKTI (ciltacabtagene autoleucel) demonstrated significantly higher rates of minimal residual disease (MRD) negativity compared to standard therapies in the CARTITUDE-4 study
- 10-Sep-2024 - Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw)
- 10-Sep-2024 - Johnson & Johnson Updates the Brand Identity of its MedTech Company Brands
- 08-Sep-2024 - RYBREVANT ® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
- 29-Aug-2024 - Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis
- 29-Aug-2024 - DePuy Synthes Launches MatrixSTERNUM™ Fixation System for Enhanced Chest Stability Following Cardiac Surgery
- Johnson & Johnson - Key Deals
- 14-Nov-2024 - Johnson & Johnson MedTech Announces Strategic Agreement with Responsive Arthroscopy to Expand Sports Soft Tissue Solutions
- 09-Oct-2024 - Johnson & Johnson Completes Acquisition of V-Wave
- 20-Aug-2024 - Johnson & Johnson to Acquire V-Wave
- 11-Jul-2024 - Johnson & Johnson strengthens pipeline to lead in atopic dermatitis with acquisition of Yellow Jersey Therapeutics
- 05-Apr-2024 - Johnson & Johnson to Acquire Shockwave Medical
- Appendix
- Definitions
- SWOT Analysis
- PESTLE Analysis
- Value Chain Analysis
- ESG Spotlight
- Financial Deep Dive
- Financial Ratios -
- Activity Ratios
- Growth Ratios
- Leverage Ratios
- Liquidity Ratios
- Market Ratios
- Profitability Ratios
- Research Methodology
- Disclaimer
- Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.